Cardiff Oncology, Inc.
CRDF· Nasdaq
CRDFCardiff Oncology, Inc.
Filed Feb 25, 2021 · 10-K · 56 days after period end · 0001628280-21-003277
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures | Q4 2017 |
|---|---|---|---|---|
| Revenue | $119.00K | $94.07K | $78.02K | $185.00K |
| Net Income | -$6.60M | -$4.24M | -$4.16M | -$2.57M |
| EPS Diluted | — | — |
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
| — |
| -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2020 · filed Feb 25, 2021 · 56 d after period end
